---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-23-000042"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2023-09-07T23:59:59+00:00"
generated_at: "2026-06-10T22:47:17.877831+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Nurix signs $60M upfront, $3.4B milestone deal with Seagen for DAC cancer drugs

## Summary
- Nurix will use DELigase platform to develop protein degraders for conjugation to antibodies by Seagen.
- Upfront cash payment of $60M; eligibility for up to $3.4B in research, development, regulatory and commercial milestones.
- Tiered royalties: mid-single to low double digits on future sales; Nurix retains option for U.S. profit sharing and co-promotion on two products.
- Seagen responsible for conjugation, preclinical/clinical development and commercialization of Degrader-Antibody Conjugates (DACs).

## SEC filing metadata
- accession: 0001549595-23-000042
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2023-09-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000042/0001549595-23-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000042/nrix-20230906.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-23-000042
- JSON: https://secwatch.observer/filing/0001549595-23-000042.json
- Plain text: https://secwatch.observer/filing/0001549595-23-000042.txt

## Key facts
- Material Agreements
  Nurix Therapeutics, Inc. entered into Collaboration Agreement with Seagen Inc. valued at $60 million (effective 2023-09-06).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Seagen Inc.
  - Value: $60 million
  - Effective: 2023-09-06
  source text: On September 6, 2023, Nurix Therapeutics, Inc. (“Nurix” or the “Company”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Seagen Inc. (“Seagen”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000042/0001549595-23-000042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.